期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

人胰腺癌CD133+/ABCG2+肿瘤细胞亚群筛选及耐药性研究

下载PDF
导出
摘要 目的:本研究筛选胰腺癌患者肿瘤组织中筛选CD133+/ABCG2+肿瘤细胞亚群。发现该亚群细胞高表达干细胞的生物标志Nanog,Oct4、SoX2等。方法:该亚群细胞在体外增殖和克隆形成能力明显增强,对于常用化疗药物顺铂和吉西他滨具有耐药性。少量该亚群细胞即可在免疫缺陷小鼠体内形成肿瘤。通过检测该亚群细胞中ABCG2基因启动子区域的CpG岛(CpG islands)DNA甲基化修饰状态。结果:表明该亚群细胞中ABCG2基因启动子区域的CpG岛处于去甲基化状态。本实验结果提示胰腺癌患者肿瘤组织中筛选CD133+/ABCG2+肿瘤细胞亚群,并利用该群细胞在体外建立了肿瘤耐药性研究模型。结论:对于胰腺癌CD133+/ABCG2+细胞研究可为开发胰腺癌个体化治疗和新型化疗药物的设计和研发提供理论依据。
作者 史坚强 陈太平 张国强 季昶 曹根宝 吴述良 张清 崔磊 仇海燕
机构地区 中国人民解放军第 江苏大学附属医院普外科
出处 《河北医学》 CAS 2014年第12期1944-1948,共5页 Hebei Medicine
基金 南京军区面上课题 (编号:12MA046)
关键词 胰腺癌 肿瘤干细胞 耐药性
分类号 R735.9 [医药卫生—肿瘤]
  • 相关文献

参考文献8

  • 1Cartwright T, Richards DA, Boehm KA. Cancer of the pan- creas : are we making progress A review of studies in the US oncology research network[ J] .Cancer Control,2008,15 (4) : 308-313.
  • 2吴庭安.吉西他滨联合希罗达治疗晚期胰腺癌的疗效比较[J].河北医学,2010,16(6):700-703. 被引量：11
  • 3Bonnet D, Dick JE. Human acute myeloid leukaemia is or- ganized as a hierarchy that originates from a primitive hema- topoietic cell[J] .Nature Med, 1997,3(7):730-743.
  • 4Al- Hajj M, Wicha MS, Benito- Hernandez A, et al. Pro- spective identification of tumorigenic breast cancer cells [ J ]. Proc Natl Acad Sci USA, 2003,100(7) :3983-3988.
  • 5Haraguchi N, Utsunomiya T, lnoue H, et al. Characteriza-tion of a side population of cancer cells from human gastroin- testinal system [ J ].Stem Cells, 2006,24 (3) : 506-513.
  • 6Kondo T, Setoguchi T and Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line[ J] .Proc Natl Acad Sci USA ,2004,101 (3) : 781-786.
  • 7Goodell MA, Brose K, Paradis G, et al. Isolation and func-tional properties of murine hematopoietic stem cells that are replicating in vivo[ J ] .Exp.Med, 1996,183 (4) : 1797-1806.
  • 8Hussain SZ, Strom SC, Kirby MR, et al. Side population ceils derived from adult human liver generate hepatocyte- like ceils in vitro[ J].Dig Dis Sci,2005, 50(10) : 1755- 1763.

二级参考文献12

  • 1张蓓,朱立勤.乳腺癌药物治疗的研究进展[J].中国药物与临床,2004,4(8):616-619. 被引量：5
  • 2李兆申.胰腺癌研究进展[J].中国实用内科杂志：临床前沿版,2006,26(12):1921-1923. 被引量：6
  • 3Freelove R,Walling AD.Pancreatic cancer:diagnosis and management[J].Am Fam Physician,2006,73 (3):485-492.
  • 4Michaud D S.Epidemiology of pancreatic cancer[J].Minerva Chir,2004,59(2):99-111.
  • 5StornioloAM,EnasNH,Brown CA,et al.An investigation news drug treatment program for patients with gemcitabine:results for over 3000 patients with pancreatic carcinoma[J].Cancer,1999,85(6):1261-1268.
  • 6Burrisha,Moorem J,Anadersen J,et al.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial[J].Clin Onco,1997,15(6):2403-2413.
  • 7DiCostanzo F,Carlini P,Doni L,et al.Gemcitabine with or without continuous imfusion 5-Fu in advanced pancreatic cancer:a randomised phaseⅡtrial of the Italian oncology group for clinical research (GOIRC)[J].Br Cancer,2005,93 (2):185-189.
  • 8OettleH,RichardsD,Ramanathan PK,et al.AphaseⅢtrial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer[J].Ann Onco,2005,16(10):1639-1645.
  • 9Rocha Lima CM,GreenMR,Rotche R,et al.Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced ormetastatic pancreatic cancer despite increased tumor response rate[J].Clin Oncol,2004,22(18):3776-3783.
  • 10Louvet C,Labianca R,Hammel P,et al.Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer:results of a GERCOR and GISCAD phaseⅢtrial[J].Clin Onco,2005,23(15):3509-3516.

共引文献10

河北医学
2014年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部